&quot;Early ph II Pilot trial of 30 Systemic Sclerosis Pts using a new antiﬁbrotic FT011 400mg vs 200mg v PBO x 12 wks showed CRISS score improved by 60% (400mg; (p=0.02 ) or 20% (200mg) at 12wks. An OL extension is planned for 9 mos @400 mg/d. https://t.co/ZU5wGXMDMC&quot;